United Therapeutics Corporation (UTHR)
United Therapeutics Corporation (UTHR) is a healthcare company (drug manufacturers - specialty & generic) based in the United States. The share price is $578.87, down 1.53% on the day, which values the company at $24.65B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $578.87−1.53% today
- Market value
- $24.65B
- P/E ratio
- 21.9×last 12 months
- Forward P/E
- 16.7×
- Funk Score
- 75/100
- Against its own history
- Well above its usual priceusual price $374.12
- 200-week average
- $352.6964% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
United Therapeutics Corporation in more detail
UTHR trades at 21.9× its last twelve months' earnings, 16.7× next year's expected earnings, 7.7× sales. Measured against its own history, the price is 55% above what its usual multiples would imply ($374.12) — well above its usual price. It sits 64% above its 200-week average of $352.69.
Over the last five fiscal years United Therapeutics Corporation has compounded revenue 16.5% a year, earnings per share 19.3% a year, free cash flow 8.3% a year. Its Funk Score is 75 out of 100 (financial strength 9.6, profitability 9.7, growth 8.2, value 2.7, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score.
4 of the superinvestors tracked here hold UTHR, including Jim Simons (1938–2024) (1.2% of the portfolio), Ray Dalio (founder) (0.2% of the portfolio), Baillie Gifford team (0.2% of the portfolio).
Superinvestors holding UTHR
4 of the investors tracked here report a position in their latest 13F filing.
- Jim Simons (1938–2024) Renaissance Technologies1.24% of portfolio · $908.2M · trimmed · Q3 2026
- Ray Dalio (founder) Bridgewater Associates0.25% of portfolio · $60.3M · added · Q2 2026
- Baillie Gifford team Baillie Gifford & Co0.19% of portfolio · $205.4M · trimmed · Q3 2026
- Israel Englander Millennium Management0.15% of portfolio · $221.6M · added · Q2 2026
Health Care companies of similar size
- Roivant SciencesROIV
- West Pharmaceutical ServicesWST
- Quest DiagnosticsDGX
- STERISSTE
- InsmedINSM
- IncyteINCY
- ViatrisVTRS
- Tenet HealthcareTHC
- BioNTechBNTX
- Guardant HealthGH
- Alnylam PharmaceuticalsALNY
- Zimmer Biomet HoldingsZBH
Side by side:UTHR vs INSM (United Therapeutics Corporation vs Insmed)UTHR vs INCY (United Therapeutics Corporation vs Incyte)UTHR vs STE (United Therapeutics Corporation vs STERIS)UTHR vs VTRS (United Therapeutics Corporation vs Viatris)UTHR vs THC (United Therapeutics Corporation vs Tenet Healthcare)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
United Therapeutics Corporation (UTHR): questions and answers
What is UTHR's P/E ratio?
United Therapeutics Corporation trades at 21.9× its last twelve months' earnings and 16.7× next year's expected earnings. At its fiscal year-ends over the past 16 years the P/E ranged from 8.1× to 150.4×, with a median of 15.1×.
What is UTHR's PEG ratio?
United Therapeutics Corporation's PEG ratio is 2.22 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is United Therapeutics Corporation's market cap?
United Therapeutics Corporation is valued at $24.65B at a share price of $578.87.
Is UTHR overvalued or undervalued?
Against its own history, UTHR is well above its usual price: the price is 55% above the $374.12 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is UTHR above its 200-week moving average?
Yes. UTHR is 64.1% above its 200-week average of $352.69. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is United Therapeutics Corporation growing?
Over the last five fiscal years United Therapeutics Corporation's revenue grew 16.5% a year and its earnings per share 19.3% a year; over ten years revenue grew 8.1% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “United Therapeutics Corporation (UTHR) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/UTHR
Underlying data: Yahoo Finance; company filings with the SEC.